Our study introduces Sema, highlighting its capacity to correct abnormal NR4a1 expression mediated by Creb5 in the TAC model, thus ameliorating metabolic dysregulation associated with myocardial remodeling. The gene discussed is NR4A1; the disease is persistent truncus arteriosus.